市場調査レポート

商品コード

1724943

注意欠陥多動性障害市場：薬剤タイプ別、年齢層別、性別、流通チャネル別、地域別、機会、予測、2018年～2032年

Attention Deficit Hyperactivity Disorder Market Assessment, By Drug Type, By Age Group, By Gender By Distribution Channel, Region, Opportunities and Forecast, 2018-2032F

出版日: 2025年05月14日
発行: Market Xcel - Markets and Data
ページ情報: 英文 246 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,500 658,440円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 834,024円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,199,824円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.32円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の注意欠陥多動性障害（ADHD）の市場規模は、予測期間の2025年～2032年のCAGRが4.33％となり、2024年の156億8,000万米ドルから2032年には220億2,000万米ドルに成長すると予測されています。世界のADHD市場は、特に学校や小児医療における認知度の向上と早期診断の取り組みによって牽引されています。研究開発投資の増加は、より安全で効果的な治療法の革新を促進しています。さらに、小児分野での旺盛な需要と、ヘルスケアインフラを有する北米の地域的優位性が、市場の成長をさらに促進しています。

例えば、2024年10月、ADHD専門家協会（AADPA）は、一般開業医のための実用的な参考資料となることを意図したリソースである「オーストラリアのヘルスケア専門家のためのADHD処方ガイド」を発表しました。このガイドでは、診断、評価、薬の選択、投与、モニタリング、副作用、移行、中止、特定の集団に対する考慮事項など、さまざまなテーマを取り上げています。主執筆者でありAADPA会長であるDavid Coghill教授によると、このガイドは、オーストラリア全土でADHDの処方に「大きなばらつき」があることを受けて作成されました。

当レポートでは、世界の注意欠陥多動性障害市場について調査し、市場の概要とともに、薬剤タイプ別、年齢層別、性別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

市場規模分析と予測
市場シェア分析と予測
- 薬剤タイプ別
  - 覚醒剤
  - 非刺激剤
- 年齢層別
  - 子供
  - 成人
- 性別
  - 男性
  - 女性
- 流通チャネル別
  - 小売薬局
  - 病院薬局
- 地域別
  - 北米
  - 欧州
  - アジア太平洋
  - 南米
  - 中東・アフリカ
- 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
2024年の市場マップ分析

第5章北米の注意欠陥多動性障害（ADHD）市場の見通し、2018年～2032年

市場規模分析と予測
市場シェア分析と予測
国別市場評価
- 米国
- カナダ
- メキシコ

第6章欧州の注意欠陥多動性障害（ADHD）市場の見通し、2018年～2032年

ドイツ
フランス
イタリア
英国
ロシア
オランダ
スペイン
トルコ
ポーランド

第7章アジア太平洋の注意欠陥多動性障害（ADHD）市場の見通し、2018年～2032年

インド
中国
日本
オーストラリア
ベトナム
韓国
インドネシア
フィリピン

第8章南米の注意欠陥多動性障害市場の見通し、2018年～2032年

ブラジル
アルゼンチン

第9章中東・アフリカの注意欠陥多動性障害市場の見通し、2018年～2032年

サウジアラビア
アラブ首長国連邦
南アフリカ

第10章需要供給分析

第11章バリューチェーン分析

第12章ポーターのファイブフォース分析

第13章 PESTLE分析

第14章価格分析

第15章市場力学

市場の促進要因
市場の課題

第16章市場動向と発展

第17章規制枠組みとイノベーション

規制当局の承認
臨床試験

第18章特許の情勢

第19章ケーススタディ

第20章競合情勢

市場リーダートップ5の競合マトリックス
参入企業トップ5のSWOT分析
市場の主要企業トップ10の情勢
- Novartis AG
- Eli Lilly and Company
- Johnson & Johnson Services, Inc.
- Lupin Limited
- Takeda Pharmaceutical Company Limited
- Mallinckrodt plc.
- Pfizer, Inc.
- Purdue Pharma L.P.
- Aytu BioPharma, Inc. (NEOS Therapeutics Inc.)
- Supernus Pharmaceuticals Inc.

第21章戦略的提言

第22章調査会社について・免責事項

図表

List of Tables

Table 1. Competition Matrix of Top 5 Market Leaders
Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 2. Global Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 3. Global Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 4. Global Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 5. Global Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 6. Global Attention Deficit Hyperactivity Disorder Market Share (%), By Region, 2018-2032F
Figure 7. North America Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 8. North America Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 9. North America Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 10. North America Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 11. North America Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 12. North America Attention Deficit Hyperactivity Disorder Market Share (%), By Country, 2018-2032F
Figure 13. United States Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 14. United States Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 15. United States Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 16. United States Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 17. United States Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 18. Canada Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 19. Canada Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 20. Canada Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 21. Canada Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 22. Canada Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 23. Mexico Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 24. Mexico Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 25. Mexico Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 26. Mexico Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 27. Mexico Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 28. Europe Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 29. Europe Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 30. Europe Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 31. Europe Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 32. Europe Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 33. Europe Attention Deficit Hyperactivity Disorder Market Share (%), By Country, 2018-2032F
Figure 34. Germany Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 35. Germany Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 36. Germany Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 37. Germany Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 38. Germany Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 39. France Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 40. France Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 41. France Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 42. France Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 43. France Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 44. Italy Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 45. Italy Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 46. Italy Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 47. Italy Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 48. Italy Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 49. United Kingdom Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 50. United Kingdom Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 51. United Kingdom Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 52. United Kingdom Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 53. United Kingdom Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 54. Russia Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 55. Russia Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 56. Russia Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 57. Russia Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 58. Russia Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 59. Netherlands Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 60. Netherlands Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 61. Netherlands Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 62. Netherlands Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 63. Netherlands Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 64. Spain Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 65. Spain Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 66. Spain Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 67. Spain Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 68. Spain Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 69. Turkey Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 70. Turkey Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 71. Turkey Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 72. Turkey Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 73. Turkey Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 74. Poland Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 75. Poland Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 76. Poland Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 77. Poland Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 78. Poland Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 79. South America Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 80. South America Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 81. South America Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 82. South America Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 83. South America Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 84. South America Attention Deficit Hyperactivity Disorder Market Share (%), By Country, 2018-2032F
Figure 85. Brazil Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 86. Brazil Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 87. Brazil Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 88. Brazil Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 89. Brazil Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 90. Argentina Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 91. Argentina Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 92. Argentina Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 93. Argentina Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 94. Argentina Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 95. Asia-Pacific Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 96. Asia-Pacific Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 97. Asia-Pacific Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 98. Asia-Pacific Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 99. Asia-Pacific Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 100. Asia-Pacific Attention Deficit Hyperactivity Disorder Market Share (%), By Country, 2018-2032F
Figure 101. India Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 102. India Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 103. India Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 104. India Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 105. India Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 106. China Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 107. China Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 108. China Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 109. China Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 110. China Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 111. Japan Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 112. Japan Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 113. Japan Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 114. Japan Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 115. Japan Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 116. Australia Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 117. Australia Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 118. Australia Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 119. Australia Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 120. Australia Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 121. Vietnam Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 122. Vietnam Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 123. Vietnam Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 124. Vietnam Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 125. Vietnam Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 126. South Korea Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 127. South Korea Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 128. South Korea Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 129. South Korea Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 130. South Korea Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 131. Indonesia Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 132. Indonesia Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 133. Indonesia Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 134. Indonesia Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 135. Indonesia Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 136. Philippines Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 137. Philippines Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 138. Philippines Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 139. Philippines Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 140. Philippines Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 141. Middle East & Africa Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 142. Middle East & Africa Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 143. Middle East & Africa Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 144. Middle East & Africa Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 145. Middle East & Africa Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 146. Middle East & Africa Attention Deficit Hyperactivity Disorder Market Share (%), By Country, 2018-2032F
Figure 147. Saudi Arabia Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 148. Saudi Arabia Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 149. Saudi Arabia Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 150. Saudi Arabia Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 151. Saudi Arabia Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 152. UAE Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 153. UAE Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 154. UAE Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 155. UAE Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 156. UAE Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 157. South Africa Attention Deficit Hyperactivity Disorder Market, By Value, In USD Billion, 2018-2032F
Figure 158. South Africa Attention Deficit Hyperactivity Disorder Market Share (%), By Drug Type, 2018-2032F
Figure 159. South Africa Attention Deficit Hyperactivity Disorder Market Share (%), By Age Group, 2018-2032F
Figure 160. South Africa Attention Deficit Hyperactivity Disorder Market Share (%), By Gender, 2018-2032F
Figure 161. South Africa Attention Deficit Hyperactivity Disorder Market Share (%), By Distribution Channel, 2018-2032F
Figure 162. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 163. By Age Group Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 164. By Gender Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 165. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Product Code: MX13120

Global attention deficit hyperactivity disorder (ADHD) market is projected to witness a CAGR of 4.33% during the forecast period 2025-2032, growing from USD 15.68 billion in 2024 to USD 22.02 billion in 2032. The global ADHD market is being driven by greater awareness and early diagnosis initiatives, especially in schools and pediatric care. Increasing R&D investments are fostering innovation in safer, more effective treatment options. Additionally, the strong demand in the pediatric segment and regional dominance of North America due to its healthcare infrastructure are further fueling market growth.

For instance, in October 2024, the ADHD Professionals Association (AADPA) has introduced the 'ADHD Prescribing Guide for Australian Healthcare Professionals,' a resource intended to serve as a practical reference for general practitioners. This guide addresses various subjects, such as diagnosis, assessment, medication selection, dosing, monitoring, side effects, transitioning, discontinuation, and considerations for specific populations. Its publication follows the 2022 release of AADPA's 'Clinical Practice Guideline for ADHD.' According to Professor David Coghill, the lead author and AADPA President, the guide was developed in response to the discovery of 'significant variability' in ADHD prescribing practices throughout Australia.

Rising Awareness and Early Diagnosis of ADHD Worldwide

The global prevalence of attention deficit hyperactivity disorder (ADHD) is driving demand for effective diagnostic and therapeutic solutions. Over the past decade, rising awareness campaigns and educational programs led by both governmental and non-governmental organizations have significantly improved early detection rates. Parents, teachers, and primary care physicians are now better equipped to identify early symptoms of ADHD in children, allowing for timely intervention. The stigma surrounding mental health is gradually reducing, and ADHD is increasingly being recognized as a manageable condition with appropriate therapy. The combination of media outreach and educational reforms has encouraged the adoption of screening protocols in schools and pediatric clinics. Moreover, technological advancements, including digital behavioral assessment tools and AI-based diagnostic systems, are also supporting early identification. For instance, in June 2024, Akili, Inc. received U.S. Food and Drug Administration (FDA) approval for EndeavorOTC, a digital treatment for adults with ADHD available without a prescription, further highlighting the shift toward digital therapeutics and proactive care.

Increasing R&D Investment and Drug Pipeline Expansion

A robust increase in research and development (R&D) investment from pharmaceutical giants is a significant growth catalyst for the global ADHD market. As neurodevelopmental disorders continue to impact millions of individuals globally, key players are investing in novel drug formulations, including extended-release medications, non-stimulants, and combination therapies to address safety concerns associated with traditional stimulants. The pipeline also includes therapies with fewer side effects and better compliance for both pediatric and adult populations. This innovation push is driven by growing market competition and the need for better patient outcomes. Additionally, clinical trials focusing on personalized medicine and targeting co-existing disorders like anxiety or depression in ADHD patients are gaining traction. Glenmark Pharmaceuticals Ltd., a prominent Indian pharmaceutical company, announced in April 2025, that its subsidiary based in the United States will introduce ADHD treatment tablets to the US market by May 2025. The formulation includes a blend of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate. These components are mixed salts derived from a single-entity amphetamine product and will be offered in five dosage strengths: 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg. The tablets are therapeutically and bioequivalent to Adderall Tablets, which is a reference drug manufactured by Teva Women's Health, Inc.

Growth of the Child Treatment Segment Boosts Market Expansion

Children remain the largest patient population diagnosed and treated for ADHD, making the pediatric segment a critical growth area in the global market. The increasing school-based screening programs and parent-reported behavioral issues have resulted in a growing number of diagnoses at earlier ages. Pharmaceutical companies are responding by developing age-appropriate formulations, such as chewable tablets, liquid suspensions, and once-daily extended-release medications to enhance compliance. Simultaneously, behavioral therapy options integrated with medication management are being promoted as part of a holistic treatment approach. Governments and educational institutions are also becoming more proactive in providing inclusive learning environments, further supporting early interventions. For instance, in August 2023, the FDA informed the public about the management of ADHD, emphasizing approved treatments designed to reduce symptoms and improve functionality, especially in children aged 6 and older. This initiative is part of broader governmental efforts to tackle ADHD in a comprehensive manner.

North America Maintains Market Leadership

North America, particularly the United States, holds the largest share in the global ADHD therapeutics market due to high awareness levels, widespread screening, and advanced treatment infrastructure. The region has a well-established healthcare system that facilitates early diagnosis and consistent follow-up. Public and private insurance coverage for mental health treatments, including ADHD medications and therapies, also boosts accessibility. In addition, favorable regulatory frameworks and high investment in research and development allow companies to introduce innovative products and receive swift approvals. There is also significant involvement from schools and pediatricians in monitoring behavioral health, which contributes to early detection and management. In November 2024, Tris Pharma, Inc. (Tris), a biopharmaceutical company in the commercial stage that specializes in attention deficit hyperactivity disorder (ADHD), pain management, addiction, and neurological conditions, has announced further regulatory approvals outside the United States for Quillivant XR (methylphenidate HCl extended-release oral suspension) and QuilliChew ER (methylphenidate HCl extended-release chewable tablets) aimed at treating ADHD.

Future Market Scenario (2025-2032F)

The global attention deficit hyperactivity disorder (ADHD) market is expected to witness steady growth in the coming years, driven by increasing prevalence across both pediatric and adult populations. Advances in digital therapeutics, precision medicine, and novel non-stimulant drugs are transforming ADHD treatment landscapes. The rise in mental health awareness, along with supportive government initiatives and improved diagnostic rates, especially in developing countries, will open new opportunities. Additionally, the integration of behavioral therapy with pharmacological treatment is gaining traction as a holistic approach. Expanding telemedicine access and e-prescriptions will further enhance diagnosis and medication adherence, especially in remote regions. With a growing focus on age-specific and gender-sensitive treatments, the ADHD therapeutics market is poised for dynamic, long-term expansion globally.

Key Players Landscape and Outlook

The key players in the market are significantly investing in the development of attention deficit hyperactivity disorder and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For example, Aytu BioPharma, Inc., a pharmaceutical firm dedicated to the commercialization of innovative therapeutics, along with Lupin Pharma Canada Ltd ("Lupin"), a subsidiary of the global pharmaceutical giant Lupin Limited, have today announced the establishment of an exclusive collaboration, distribution, and supply agreement concerning Aytu's Adzenys XR-ODT and Cotempla XR-ODT product lines in Canada. Adzenys XR-ODT, an extended-release orally disintegrating tablet, is a prescription medication indicated for the treatment of attention deficit hyperactivity disorder ("ADHD") in patients aged 6 years and older and is the sole brand that has received FDA approval as a bioequivalent to Adderall XR. Cotempla XR-ODT is recognized as the only extended-release orally disintegrating tablet formulation of methylphenidate, which is FDA-approved for once-daily administration in the treatment of ADHD for patients aged 6 to 17 years.

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Attention Deficit Hyperactivity Disorder Market Outlook, 2018-2032F

4.1. Market Size Analysis & Forecast
- 4.1.1. By Value
4.2. Market Share Analysis & Forecast
- 4.2.1. By Drug Type
  - 4.2.1.1. Stimulants
    - 4.2.1.1.1. Amphetamine
    - 4.2.1.1.2. Methylphenidate
    - 4.2.1.1.3. Lisdexamfetamine
    - 4.2.1.1.4. Dexmethylphenidate
    - 4.2.1.1.5. Dextroamphetamine
  - 4.2.1.2. Non-stimulants
    - 4.2.1.2.1. Atomoxetine
    - 4.2.1.2.2. Guanfacine
    - 4.2.1.2.3. Clonidine
    - 4.2.1.2.4. Other non-stimulants
- 4.2.2. By Age Group
  - 4.2.2.1. Children
  - 4.2.2.2. Adult
- 4.2.3. By Gender
  - 4.2.3.1. Male
  - 4.2.3.2. Female
- 4.2.4. By Distribution Channel
  - 4.2.4.1. Retail Pharmacy
  - 4.2.4.2. Hospital Pharmacy
- 4.2.5. By Region
  - 4.2.5.1. North America
  - 4.2.5.2. Europe
  - 4.2.5.3. Asia-Pacific
  - 4.2.5.4. South America
  - 4.2.5.5. Middle East and Africa
- 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
4.3. Market Map Analysis, 2024
- 4.3.1. By Drug Type
- 4.3.2. By Age Group
- 4.3.3. By Gender
- 4.3.4. By Distribution Channel
- 4.3.5. By Region

5. North America Attention Deficit Hyperactivity Disorder Market Outlook, 2018-2032F

5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
5.2. Market Share Analysis & Forecast
- 5.2.1. By Drug Type
  - 5.2.1.1. Stimulants
    - 5.2.1.1.1. Amphetamine
    - 5.2.1.1.2. Methylphenidate
    - 5.2.1.1.3. Lisdexamfetamine
    - 5.2.1.1.4. Dexmethylphenidate
    - 5.2.1.1.5. Dextroamphetamine
  - 5.2.1.2. Non-stimulants
    - 5.2.1.2.1. Atomoxetine
    - 5.2.1.2.2. Guanfacine
    - 5.2.1.2.3. Clonidine
    - 5.2.1.2.4. Other non-stimulants
- 5.2.2. By Age Group
  - 5.2.2.1. Children
  - 5.2.2.2. Adult
- 5.2.3. By Gender
  - 5.2.3.1. Male
  - 5.2.3.2. Female
- 5.2.4. By Distribution Channel
  - 5.2.4.1. Retail Pharmacy
  - 5.2.4.2. Hospital Pharmacy
- 5.2.5. By Country Share
  - 5.2.5.1. United States
  - 5.2.5.2. Canada
  - 5.2.5.3. Mexico
5.3. Country Market Assessment
- 5.3.1. United States Attention Deficit Hyperactivity Disorder Market Outlook, 2018-2032F*
  - 5.3.1.1. Market Size Analysis & Forecast
    - 5.3.1.1.1. By Value
  - 5.3.1.2. Market Share Analysis & Forecast
    - 5.3.1.2.1. By Drug Type
      - 5.3.1.2.1.1. Stimulants
      - 5.3.1.2.1.1.1. Amphetamine
      - 5.3.1.2.1.1.2. Methylphenidate
      - 5.3.1.2.1.1.3. Lisdexamfetamine
      - 5.3.1.2.1.1.4. Dexmethylphenidate
      - 5.3.1.2.1.1.5. Dextroamphetamine
      - 5.3.1.2.1.2. Non-stimulants
      - 5.3.1.2.1.2.1. Atomoxetine
      - 5.3.1.2.1.2.2. Guanfacine
      - 5.3.1.2.1.2.3. Clonidine
      - 5.3.1.2.1.2.4. Other non-stimulants
    - 5.3.1.2.2. By Age Group
      - 5.3.1.2.2.1. Children
      - 5.3.1.2.2.2. Adult
    - 5.3.1.2.3. By Gender
      - 5.3.1.2.3.1. Male
      - 5.3.1.2.3.2. Female
    - 5.3.1.2.4. By Distribution Channel
      - 5.3.1.2.4.1. Retail Pharmacy
      - 5.3.1.2.4.2. Hospital Pharmacy
- 5.3.2. Canada
- 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Attention Deficit Hyperactivity Disorder Market Outlook, 2018-2032F

6.1. Germany
6.2. France
6.3. Italy
6.4. United Kingdom
6.5. Russia
6.6. Netherlands
6.7. Spain
6.8. Turkey
6.9. Poland

7. Asia-Pacific Attention Deficit Hyperactivity Disorder Market Outlook, 2018-2032F

7.1. India
7.2. China
7.3. Japan
7.4. Australia
7.5. Vietnam
7.6. South Korea
7.7. Indonesia
7.8. Philippines

8. South America Attention Deficit Hyperactivity Disorder Market Outlook, 2018-2032F

8.1. Brazil
8.2. Argentina

9. Middle East and Africa Attention Deficit Hyperactivity Disorder Market Outlook, 2018-2032F

9.1. Saudi Arabia
9.2. UAE
9.3. South Africa

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

15.1. Market Drivers
15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

17.1. Regulatory Approvals
17.2. Clinical Trials

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

20.1. Competition Matrix of Top 5 Market Leaders
20.2. SWOT Analysis for Top 5 Players
20.3. Key Players Landscape for Top 10 Market Players
- 20.3.1. Novartis AG
  - 20.3.1.1. Company Details
  - 20.3.1.2. Key Management Personnel
  - 20.3.1.3. Products and Services
  - 20.3.1.4. Financials (As Reported)
  - 20.3.1.5. Key Market Focus and Geographical Presence
  - 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
- 20.3.2. Eli Lilly and Company
- 20.3.3. Johnson & Johnson Services, Inc.
- 20.3.4. Lupin Limited
- 20.3.5. Takeda Pharmaceutical Company Limited
- 20.3.6. Mallinckrodt plc.
- 20.3.7. Pfizer, Inc.
- 20.3.8. Purdue Pharma L.P.
- 20.3.9. Aytu BioPharma, Inc. (NEOS Therapeutics Inc.)
- 20.3.10. Supernus Pharmaceuticals Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

注意欠陥多動性障害市場：薬剤タイプ別、年齢層別、性別、流通チャネル別、地域別、機会、予測、2018年～2032年

Attention Deficit Hyperactivity Disorder Market Assessment, By Drug Type, By Age Group, By Gender By Distribution Channel, Region, Opportunities and Forecast, 2018-2032F

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の注意欠陥多動性障害（ADHD）市場の見通し、2018年～2032年

第5章 北米の注意欠陥多動性障害（ADHD）市場の見通し、2018年～2032年

第6章 欧州の注意欠陥多動性障害（ADHD）市場の見通し、2018年～2032年

第7章 アジア太平洋の注意欠陥多動性障害（ADHD）市場の見通し、2018年～2032年

第8章 南米の注意欠陥多動性障害市場の見通し、2018年～2032年

第9章 中東・アフリカの注意欠陥多動性障害市場の見通し、2018年～2032年

第10章 需要供給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析